REGISTER
DFU Treatment: LLLT, Bedside Amputation, and Immune Healing at EASD 2026
Three EASD 2026 studies advanced DFU care. An RCT (n=32) of low-level laser therapy for Texas 1A neuropathic DFU showed faster healing (7.14 vs 9.84 weeks, p=0.028), though healing rates did not differ. A pre/post study (n=761) linked bedside bone biopsy and toe amputation to -37% lower-limb amputation, -54% major amputation, and -70% operating room use. A proteomic study (n=12) identified early transient inflammation followed by repair activation as signatures of successful healing.

At the European Association for the Study of Diabetes (EASD) Annual Meeting 2026, three studies advanced the multidisciplinary management of diabetic foot ulcer (DFU), spanning adjunctive physical therapy, surgical strategy, and healing immunology.

Article Key Points

- LLLT + standard care vs standard care for Texas 1A neuropathic DFU: faster healing (7.14 vs 9.84 weeks, p=0.028)

- Healing rates did not differ significantly (87.5% vs 75.0%, p=0.365); no LLLT-related adverse events reported

- Bedside bone biopsy and toe amputation linked to -37% LLA, -54% major amputation, -70% OR use (n=761)

- Proteomic study (n=12): healing patients showed CCL4-driven inflammation that declined over time, with repair activation

- Evidence status: conference abstracts; full results have not yet been peer-reviewed

Low-Level Laser Therapy: Faster Healing in Neuropathic DFU, Good Safety

Study design: Randomized controlled trial conducted at the Mansoura Diabetic Foot Clinic, Egypt. Population: 32 patients with Texas grade 1A neuropathic DFU, randomized 1:1 to LLLT plus standard care (n=16) or standard care alone (n=16). Standard care included surgical debridement every two weeks and appropriate offloading. LLLT was delivered three times weekly for 12 weeks at wavelengths of 650-1000 nm and energy density 4-6 J/cm². Primary outcomes were complete ulcer healing rate and time to complete healing.

Results: Complete healing rate was 87.5% in the LLLT arm versus 75.0% in controls, a non-significant between-group difference (p=0.365). However, mean time to complete healing was significantly shorter in the LLLT arm (7.14 ± 3.20 weeks) than in controls (9.84 ± 2.48 weeks; p=0.028). The LLLT arm received significantly more treatment sessions, and the number of laser sessions was strongly positively correlated with healing time (r=0.739, p=0.003), suggesting that slower healers received more sessions. No LLLT-related adverse events were reported.

This small RCT suggests that LLLT can significantly shorten healing time in neuropathic DFU with a good safety profile, providing preliminary support for incorporating LLLT as an adjunct in multidisciplinary DFU management.

Bedside Bone Biopsy and Toe Amputation: Major Reductions in Amputation Rates and Operating Room Use

Study design: Single-center observational study comparing outcomes in patients hospitalized for DFU before and after implementation of routine bedside bone biopsy (B4) and bedside toe amputation surgery (BTAS) performed by trained diabetes specialists, alongside increased revascularization (RVZ) at Lariboisière Hospital, Paris, France. Population: 761 hospitalized DFU patients, including 280 in 2013-2015 and 481 in 2023-2025. Major amputation was defined as transtibial or transfemoral. Multivariable logistic regression assessed the association of B4, BTAS, and RVZ with lower-limb amputation (LLA) outcomes.

Results: Baseline characteristics and DFU severity were similar across the two periods (median SINBAD score 4). Overall, 57% of DFUs involved one or two toes, and 58% had necrosis. Compared with 2013-2015, in 2023-2025 the total LLA rate fell from 52% to 33% (-37%; p=5×10⁻⁷), the major amputation rate fell from 21.1% to 9.8% (-54%; p=0.0007), and the operating room amputation rate fell from 47% to 14% (-70%; p=1×10⁻²²). In multivariable analysis, B4 and BTAS were independently associated with lower LLA rates, while RVZ showed no such association.

The findings suggest that bedside bone biopsy and toe amputation performed by trained diabetes specialists are associated with significant reductions in overall amputation, major amputation, and operating room use in hospitalized DFU patients.

Early Transient Systemic Inflammation: An Immune Network Signature of Successful DFU Healing

Study design: Prospective study of 12 DFU patients treated at a multidisciplinary foot clinic. Peripheral blood was sampled at baseline, 4-8 weeks, and 8-16 weeks. The analysis integrated 184 circulating proteins, 21 clinical variables, and 29 longitudinal samples using network-based computational simulation. Ulcers were classified at the third visit as healed (complete closure or >50% area reduction) or unhealed.

Results: Different longitudinal protein modules were associated with healing. Counter-intuitively, healing patients showed stronger baseline activation of an inflammatory module; CCL4 was identified as the driver protein and significantly decreased in later follow-ups (p<0.05). At the same time, healing patients showed enrichment over time of a repair-related trajectory including migration, proliferation, and tissue remodeling proteins (p<0.05), with CHL1 and COMP emerging as later driver proteins. Single-cell mapping localized early CCL4 primarily to circulating T cells and to macrophage/myeloid cell populations in ulcer tissue.

The findings suggest that successful DFU healing is characterized by an early but self-limited systemic inflammatory response followed by activation of repair pathways. These temporal immune network features offer candidate biomarkers and therapeutic targets for improving DFU outcomes.

Conclusion

Three studies advanced comprehensive care for DFU. LLLT accelerated healing in neuropathic DFU with a good safety profile. Bedside bone biopsy combined with bedside toe amputation significantly reduced amputation rates and operating room use. Longitudinal immune network analysis revealed that successful healing is accompanied by an early self-limited inflammatory response followed by repair pathway activation. Future integration of these findings into multidisciplinary DFU pathways could enable more precise healing prediction and individualized intervention. Larger studies are warranted to validate clinical utility and explore whether combination strategies can further improve DFU outcomes.

0
0
Loading